Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Black Diamond Therapeutics Inc (BDTX)

Black Diamond Therapeutics Inc (BDTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 262,210
  • Shares Outstanding, K 51,718
  • Annual Sales, $ 0 K
  • Annual Income, $ -82,440 K
  • 60-Month Beta 2.65
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.25
Trade BDTX with:

Options Overview Details

View History
  • Implied Volatility 124.14% ( +11.44%)
  • Historical Volatility 91.10%
  • IV Percentile 50%
  • IV Rank 14.63%
  • IV High 735.97% on 10/19/23
  • IV Low 19.30% on 11/29/23
  • Put/Call Vol Ratio 0.30
  • Today's Volume 43
  • Volume Avg (30-Day) 79
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 1,439
  • Open Int (30-Day) 1,953

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.44
  • Number of Estimates 5
  • High Estimate -0.40
  • Low Estimate -0.52
  • Prior Year -0.57
  • Growth Rate Est. (year over year) +22.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.72 +36.29%
on 03/12/24
5.88 -13.78%
on 03/22/24
+0.12 (+2.42%)
since 02/28/24
3-Month
2.53 +100.40%
on 01/05/24
5.88 -13.78%
on 03/22/24
+2.04 (+67.33%)
since 12/28/23
52-Week
1.43 +254.55%
on 05/01/23
6.85 -25.99%
on 06/27/23
+3.22 (+174.05%)
since 03/28/23

Most Recent Stories

More News
Black Diamond: Q4 Earnings Snapshot

Black Diamond: Q4 Earnings Snapshot

BDTX : 5.07 (+3.47%)
Black Diamond: Q3 Earnings Snapshot

Black Diamond: Q3 Earnings Snapshot

BDTX : 5.07 (+3.47%)
Black Diamond: Q2 Earnings Snapshot

Black Diamond: Q2 Earnings Snapshot

BDTX : 5.07 (+3.47%)
Stocks Set to Open Lower as Investors Await U.S. Inflation Data and Big Bank Earnings, Chinese Inflation Data Disappoints

September S&P 500 futures (ESU23) are down -0.04%, and September Nasdaq 100 E-Mini futures (NQU23) are down -0.05% this morning as weak inflation data from China added to a gloomy global economic outlook...

ESU23 : 4,491.72s (-0.32%)
NQU23 : 15,435.20s (-0.28%)
LEVI : 19.99 (+3.20%)
COST : 732.63 (+0.08%)
ZION : 43.40 (+0.58%)
CMA : 54.99 (+1.40%)
JPM : 200.30 (+0.39%)
WFC : 57.96 (+0.61%)
C : 63.24 (+0.78%)
BAYN.D.DX : 28.410 (+0.04%)
BDTX : 5.07 (+3.47%)
SCHW : 72.34 (-0.06%)
Why Shares of Black Diamond Therapeutics Skyrocketed This Week

The company announced positive early-trial news for non-small cell lung cancer.

BDTX : 5.07 (+3.47%)
Black Diamond Therapeutics’ (NASDAQ: BDTX) BDTX-1535 Proves Promising for EGFR Mutated NSCLC and GBM

Black Diamond Therapeutics has announced encouraging initial data from a Phase 1 study of BDTX-1535, an investigational fourth-generation EGFR MasterKey

BDTX : 5.07 (+3.47%)
Black Diamond: Q1 Earnings Snapshot

Black Diamond: Q1 Earnings Snapshot

BDTX : 5.07 (+3.47%)
Black Diamond: Q4 Earnings Snapshot

Black Diamond: Q4 Earnings Snapshot

BDTX : 5.07 (+3.47%)
Down 32.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Black Diamond (BDTX)

Black Diamond (BDTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates...

BDTX : 5.07 (+3.47%)
Black Diamond: Q3 Earnings Snapshot

Black Diamond: Q3 Earnings Snapshot

BDTX : 5.07 (+3.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Black Diamond Therapeutics Inc. is an oncology medicine company. It engages in discovery and development of small molecule, tumor-agnostic therapies. The company's lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor...

See More

Key Turning Points

3rd Resistance Point 5.50
2nd Resistance Point 5.38
1st Resistance Point 5.23
Last Price 5.07
1st Support Level 4.95
2nd Support Level 4.83
3rd Support Level 4.68

See More

52-Week High 6.85
Last Price 5.07
Fibonacci 61.8% 4.78
Fibonacci 50% 4.14
Fibonacci 38.2% 3.50
52-Week Low 1.43

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar